Jan 20, 2021
We sit down and talk to Dr. Abribat about Amolyt Pharma, which is developing therapeutic peptides to treat rare endocrine and metabolic diseases. The company recently announced that it has dosed the first patient in a Phase 1 clinical trial evaluating its experimental therapeutic peptide, AZP-3601, for a...
Jan 13, 2021
Dr. David Horn Solomon, CEO of Pharnext discusses PXT3003 which
is currently focused on the treatment of Charcot Marie-Tooth (CMT)
disease Type 1A.
Charcot-Marie-Tooth is a degenerative nerve disease that usually
appears in adolescence or early adulthood. CMT affects the
Peripheral Nervous System. It is a progressive...
Jan 6, 2021
Dr. Lenze discusses a clinical trial conducted by Washington University School of Medicine in St. Louis which evidences the potential that fluvoxamine, an antidepressant, may prevent COVID-19 infections from worsening. This trial is based on recent research that originates from the University of Virginia School...
Dec 23, 2020
Dr. Ragen discusses X4 Pharmaceuticals, which is currently developing therapies for rare genetic diseases that result from dysfunction of the immune system and is currently undergoing a global Phase 3 trial for WHIM Syndrome and two Phase 1b trials for Waldenstrom macroglobulinemia (WM), a type of rare lymphoma,...
Dec 16, 2020
We sit down with Dr. CJ Barnum, Director of Neuroscience at Inmune Bio, Inc. to talk about the recently announced grant from the NIH for $2.9 million to test a new hypothesis that #neuroinflammation plays a major role in treatment resistant depression (TRD).
This money will support a first-of-its-kind phase 2 study...